Business Context and Reporting Period
This Form 8-K Current Report is filed by Bristol-Myers Squibb Company (BMY) on November 15, 2019. The filing addresses two primary events: the receipt of final regulatory approval for the pending merger with Celgene Corporation and an update regarding the expiration of exchange offers for Celgene notes.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain periodic financial statements. Consequently, specific metrics such as revenue, profit, cash flow, margins, debt levels, and liquidity ratios are not provided in this document.
However, the filing references the following financial instruments and transaction values:
- Exchange Offers: Offers to exchange Celgene notes with an aggregate principal amount of up to $19,850,000,000 for new notes issued by Bristol-Myers Squibb and cash.
- Divestiture: A required divestiture of Celgene's OTEZLA (apremilast) business to Amgen Inc. within 10 days following the merger closing.
Material Changes and Events
The filing reports the following material developments:
- FTC Approval: The Federal Trade Commission accepted a proposed consent order on November 15, 2019, allowing the merger with Celgene to proceed subject to conditions, including the OTEZLA divestiture.
- Regulatory Clearance: All regulatory approvals required for the consummation of the merger have been obtained.
- Merger Closing: The companies expect to close the merger on November 20, 2019.
- Exchange Offer Expiration: Bristol-Myers Squibb announced it expects no further extensions of the expiration date for the exchange offers and consent solicitations, which are scheduled to expire on November 20, 2019.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The company anticipates the merger will close on November 20, 2019, with the settlement of exchange offers expected on November 22, 2019. The combined company is expected to have substantial indebtedness following the transaction.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, highlighting risks such as:
- Failure to complete the transaction on anticipated terms or timing.
- Inability to achieve synergies or effectively integrate Celgene's businesses.
- Diversion of management attention and operational disruption.
- Potential decline in credit ratings for the combined company.
- Legal proceedings and inability to retain key personnel.
Investor Verification Checklist
- Verify the final closing date of the merger (anticipated November 20, 2019) and confirm completion.
- Monitor the divestiture of the OTEZLA business to Amgen Inc., which must occur within 10 days of the merger closing.
- Review the definitive joint proxy statement/prospectus (Form S-4) for detailed financial impacts and debt structures.
- Confirm the settlement of the exchange offers for Celgene notes on or around November 22, 2019.
- Assess the impact of the transaction on the combined company's credit ratings and indebtedness levels.